Medios AG

ILM1

DE000A1MMCC8

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:36:09 2024-05-17 am EDT			5-day change	1st Jan Change
14.48 ^EUR	+2.70%		+2.99%	-8.70%

May. 07	Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Transcript : Medios AG, Q1 2024 Earnings Call, May 07, 2024

MEDIOS : Deutsche Bank reiterates its Buy rating

November 11, 2022 at 07:03 am EST

In a research note published by Michael Kuhn, Deutsche Bank advises its customers to buy the stock. The target price is reduced from EUR 50 to EUR 30.

Latest news about Medios AG

Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Transcript : Medios AG, Q1 2024 Earnings Call, May 07, 2024	May. 06
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Medios AG Provides Earnings Guidance for the Year 2024	Mar. 17	CI
Transcript : Medios AG, Ceban B.V. - M&A Call	Mar. 17
Medios AG agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for ? 259 million.	Mar. 17	CI
Medios AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : Medios AG, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Medios AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Medios AG, H1 2023 Earnings Call, Aug 14, 2023	23-08-13
Medios to Sell Kölsche Blister Unit Amid Plan to Centralize Blister Business in Germany	23-06-19	MT
Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Medios AG, Q1 2023 Earnings Call, May 11, 2023	23-05-10
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Medios AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Transcript : Medios AG, 2022 Earnings Call, Mar 30, 2023	23-03-29
Medios: Countering price pressure in specialty pharmaceuticals - 2022 targets achieved	23-01-31	DP
Medios aims to counter price pressure in specialty pharmaceuticals - 2022 targets achieved	23-01-31	DP
Medios Closes Purchase of Germany's Blisterzentrum Baden-Württemberg	23-01-10	MT
Medios AG completed the acquisition of Blisterzentrum Baden-Württemberg GmbH.	23-01-09	CI
Medios AG(XTRA:ILM1) dropped from Germany SDAX (Total Return) Index	22-12-16	CI
MEDIOS : Buy rating from Deutsche Bank	22-11-25	ZD
MEDIOS : Warburg Research reiterates its Buy rating	22-11-25	ZD
MEDIOS : Jefferies reiterates its Buy rating	22-11-23	ZD
MEDIOS : Deutsche Bank reiterates its Buy rating	22-11-23	ZD

Medios AG, formerly Crevalis Capital AG, is a Germany-based company that is active in the pharmacy business. It wholesales, markets, distributes and produces various kinds of goods for pharmacies and other pharmaceutical companies. The Company also provides related services and is engaged in the acquisition and management of other companies from the pharmaceutical industry.

Sector

Pharmaceuticals

Calendar

2024-06-05 - Warburg Highlights Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Medios AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.48 EUR

Average target price

34.75 EUR

Spread / Average Target

+139.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDIOS AG	-8.70%	375M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

Medios AG

Equities

ILM1

DE000A1MMCC8

Pharmaceuticals

MEDIOS : Deutsche Bank reiterates its Buy rating

Latest news about Medios AG

Chart Medios AG

Company Profile

Income Statement Evolution

Ratings for Medios AG

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals